0

Month: December 2016

Stanley Hazen, MD, PhD Joins Roster of Expert Faculty for The 12th Annual CMHC

The Cardiometabolic Health Congress has announced Stanley Hazen, MD, PhD, Head of the Section for Preventive Cardiology and Rehabilitation of the Cleveland Clinic as its Keynote speaker for the 12th Annual CMHC, taking place October 4-7, 2017, at the Sheraton in Boston, MA. Specializing in preventive cardiovascular care, including the treatment of hyperlipidemia, diabetes, hypertension, and obesity, Dr. Hazen will discuss his groundbreaking work concerning gut microbes as a factor and therapeutic target in cardiometabolic diseases. Dr. Hazen has received numerous awards including election to membership in honorary societies in science and clinical arenas alike and also serves as reviewer and/or is on the editorial board for many scientific journals, including Circulation and the Journal of Lipid Research.

2017 ADA Standards of Medical Care in Diabetes Emphasize Psychological Health and Personalized Treatment Options

The newly published 2017 Standards of Medical Care in Diabetes by the American Diabetes Association emphasize psychological health, access to care, expanded and personalized treatment options, as well as hypoglycemia tracking in patients with diabetes as critical areas of focus.

In addition to screening, diagnosis, and treatment options, including metabolic surgery, that will provide better outcomes for patients with diabetes and information to improve the prevention/delay of type 2 diabetes, the guidelines also include data from a report that focused on beta-cell dysfunction and describes approaches to clarify specific subtypes of diabetes to facilitate personalized care.

The Standards also specifically include a recommendation to consider the use of empagliflozin in patients with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death.

References:

ADA: 2017 Standards of Medical Care in Diabetes Released.

2017 Standards of Medical Care in Diabetes.

Boehringer Ingelheim and Lilly welcome new recommendation for Jardiance® (empagliflozin) tablets in updated American Diabetes Association’s 2017 Standards.